How I Got Hooked by Scleroderma

Pulmonary hypertension (PH), being a serious complication of systemic sclerosis (SSc), develops late in the course of SSc and carries with it a poor prognosis. With the median survival of about 3 years, new evidence suggests that early diagnosis and treatment can significantly improve survival. Joining us this week is Christopher P Denton PhD FRCP, senior author of “Dynamic Prediction of Pulmonary Hypertension in Systemic Sclerosis Using Landmark Analysis,” published in Arthritis and Rheumatology. Dr. Denton’s latest study explores “the prediction of short-term risk for PH using serial pulmonary function tests (PFTs)”